Indirubin derivative 6BIO suppresses metastasis

Cancer Research

Volumn 73, Issue 19, 2013, Pages 6004-6012

  Braig, Simone ^a   Kressirer, Christine A ^a   Liebl, Johanna ^a   Bischoff, Fabian ^a   Zahler, Stefan ^a   Meijer, Laurent ^b   Vollmar, Angelika M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b STATION BIOLOGIQUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

6 BROMO INDIRUBIN 3' OXIME; ANTIMETASTATIC AGENT; CARBOXY TERMINAL TENSIN LIKE PROTEIN; FIBRONECTIN; GELATINASE A; INDIRUBIN; JANUS KINASE; JANUS KINASE INHIBITOR; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; REGULATOR PROTEIN; SARACATINIB; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PHENOTYPE; POLYPHARMACY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TREATMENT RESPONSE; TUMOR INVASION; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHEMOTAXIS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INDOLES; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MICE; MICE, INBRED BALB C; OXIMES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; STAT TRANSCRIPTION FACTORS;

EID: 84885058109     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-4358     Document Type: Article

References (47)

1. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science 2011;331:1559-64.
2. Weigelt B, Peterse JL, van 't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
4. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
5. Petrelli A, Giordano S. From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem 2008;15:422-32.
6. Levitzki A, Klein S. Signal transduction therapy of cancer. Mol Aspects Med 2010;31:287-329.
7. Graham JG, Quinn ML, Fabricant DS, Farnsworth NR. Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol 2000;73:347-77.
8. Newman DJ, Cragg GM. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod 2012;75:311-35.
9. Yang G, Li X, Li X, Wang L, Li J, Song X, et al. Traditional chinese medicine in cancer care: a review of case series published in the chinese literature. Evid Based Complement Alternat Med 2012;2012:751046.
10. Xiao Z, Hao Y, Liu B, Qian L. Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leuk Lymphoma 2002;43:1763-8.
11. Eisenbrand G, Hippe F, Jakobs S, Muehlbeyer S. Molecular mechanisms of indirubin and its derivatives: novel anticancer molecules with their origin in traditional Chinese phytomedicine. J Cancer Res Clin Oncol 2004;130:627-35.
12. Meijer L, Guyard N, Skaltsounis LA, Eisenbrand G. ed. Indirubin, the red shape of indigo. Life in Progress 2006: Station Biologique, Roscoff, France.
13. Bradbury J. From Chinese medicine to anticancer drugs. Drug Discov Today 2005;10:1131-2.
14. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999;1:60-7.
15. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, et al. GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 2003;10:1255-66.
16. Liebl J, Weitensteiner SB, Vereb G, Takacs L, Furst R, Vollmar AM, et al. Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem 2010;285:35932-43.
17. Rath S, Liebl J, Furst R, Ullrich A, Burkhart J, Kazmaier U, et al. Antiangiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives. Br J Pharmacol 2012;167:1048-61.
18. Rothmeier AS, Ischenko I, Joore J, Garczarczyk D, Furst R, Bruns CJ, et al. Investigation of the marine compound spongistatin 1 links the inhibition of PKCalpha translocation to nonmitotic effects of tubulin antagonism in angiogenesis. FASEB J 2009;23:1127-37.
19. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
20. Braig S, Bosserhoff AK. Death inducer-obliterator 1 (Dido1) is a BMP target gene and promotes BMP-induced melanoma progression. Oncogene 2013;32:837-48.
21. Zahler S, Tietze S, Totzke F, Kubbutat M, Meijer L, Vollmar AM, et al. Inverse in silico screening for identification of kinase inhibitor targets. Chem Biol 2007;14:1207-14.
22. Tao K, Fang M, Alroy J, Sahagian GG. Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer 2008;8:228.
23. Sato N, Meijer L, Skaltsounis L, Greengard P, Brivanlou AH. Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitor. Nat Med 2004;10:55-63.
24. Wang FS, Ko JY, Weng LH, Yeh DW, Ke HJ, Wu SL. Inhibition of glycogen synthase kinase-3beta attenuates glucocorticoid-induced bone loss. Life Sci 2009;85:685-92.
25. Martin L, Magnaudeix A, Esclaire F, Yardin C, Terro F. Inhibition of glycogen synthase kinase-3beta downregulates total tau proteins in cultured neurons and its reversal by the blockade of protein phosphatase-2A. Brain Res 2009;1252:66-75.
26. Ribas J, Bettayeb K, Ferandin Y, Knockaert M, Garrofe-Ochoa X, Totzke F, et al. 7-Bromoindirubin-30-oxime induces caspase-independent cell death. Oncogene 2006;25:6304-18.
27. Liu L, Nam S, Tian Y, Yang F, Wu J, Wang Y, et al. 6-Bromoindirubin-30- oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells. Cancer Res 2011;71:3972-9.
28. Nicolaou KA, Liapis V, Evdokiou A, Constantinou C, Magiatis P, Skaltsounis AL, et al. Induction of discrete apoptotic pathways by bromo-substituted indirubin derivatives in invasive breast cancer cells. Biochem Biophys Res Commun 2012;425:76-82.
29. Williams SP, Nowicki MO, Liu F, Press R, Godlewski J, Abdel-Rasoul M, et al. Indirubins decrease glioma invasion by blocking migratory phenotypes in both the tumor and stromal endothelial cell compartments. Cancer Res 2011;71:5374-80.
30. Yoeli-Lerner M, Chin YR, Hansen CK, Toker A. Akt/protein kinase b and glycogen synthase kinase-3beta signaling pathway regulates cell migration through the NFAT1 transcription factor. Mol Cancer Res 2009;7:425-32.
31. Zhou BP, Deng J, Xia W, Xu J, Li YM, Gunduz M, et al. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelialmesenchymal transition. Nat Cell Biol 2004;6:931-40.
32. Liu Y, Wang J, Wu M, Wan W, Sun R, Yang D, et al. Down-regulation of 3-phosphoinositide-dependent protein kinase-1 levels inhibits migration and experimental metastasis of human breast cancer cells. Mol Cancer Res 2009;7:944-54.
33. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al. Overexpression of AKT2/protein kinase Bbeta leads to upregulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003;63:196-206.
34. Irie HY, Pearline RV, Grueneberg D, Hsia M, Ravichandran P, Kothari N, et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial-mesenchymal transition. J Cell Biol 2005;171:1023-34.
35. Schlessinger K, Levy DE. Malignant transformation but not normal cell growth depends on signal transducer and activator of transcription 3. Cancer Res 2005;65:5828-34.
36. Gao SP, Bromberg JF. Touched and moved by STAT3. Sci STKE 2006;2006:pe30.
37. Yeh TC, Pellegrini S. The Janus kinase family of protein tyrosine kinases and their role in signaling. Cell Mol Life Sci 1999;55:1523-34.
38. Ingley E, Klinken SP. Cross-regulation of JAK and Src kinases. Growth Factors 2006;24:89-95.
39. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
40. Zhang X, Yue P, Page BD, Li T, Zhao W, Namanja AT, et al. Orally bioavailable small-molecule inhibitor of transcription factor Stat3 regresses human breast and lung cancer xenografts. Proc Natl Acad Sci U S A 2012;109:9623-8.
41. Zhang S, Yu D. Targeting Src family kinases in anti-cancer therapies: turning promise into triumph. Trends Pharmacol Sci 2012;33:122-8.
42. Senft C, Priester M, Polacin M, Schroder K, Seifert V, Kogel D, et al. Inhibition of the JAK-2/STAT3 signaling pathway impedes the migratory and invasive potential of human glioblastoma cells. J Neurooncol 2011;101:393-403.
43. Tsareva SA, Moriggl R, Corvinus FM, Wiederanders B, Schutz A, Kovacic B, et al. Signal transducer and activator of transcription 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase induction. Neoplasia 2007;9:279-91.
44. Barbieri I, Pensa S, Pannellini T, Quaglino E, Maritano D, Demaria M, et al. Constitutively active Stat3 enhances neu-mediated migration and metastasis in mammary tumors via upregulation of Cten. Cancer Res 2010;70:2558-67.
45. Katz M, Amit I, Citri A, Shay T, Carvalho S, Lavi S, et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 2007;9:961-9.
46. Rosen LS, Ashurst HL, Chap L. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010;15:216-35.
47. Levitzki A. Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu Rev Pharmacol Toxicol 2013;53:161-85.